suPAR Health Test

Since the discovery of suPAR (soluble urokinase plasminogen activator receptor) in the 1990s, it has gained international recognition as a stable and reproducible marker of chronic inflammation. SuPAR has significantly contributed to the understanding of chronic inflammation as a key underlying factor in the development of a wide range of diseases and as a predictor of survival, both in healthy individuals and in patients.

With more than 25 years of research and over 1,000 peer-reviewed publications, suPAR has proven its clinical value and is increasingly being used in hospitals and laboratories around the world.

What We Know Today

Elevated suPAR levels have been consistently associated with accelerated biological aging, increased risk of disease, greater disease severity, and higher mortality risk. These findings have been demonstrated across both healthy populations and various disease groups, with more than one million tests conducted to date.

SuPAR plays an important role in immune activation and systemic inflammation, which has made it a valuable tool for predicting disease progression and guiding treatment strategies. It is also the first biomarker to be approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for guiding treatment decisions in infectious diseases.

In recent years, suPAR has become increasingly relevant in the fields of early disease detection, preventive health, and longevity for the following reasons:
1. Higher suPAR levels are associated with faster biological aging, and the marker can predict the onset of common chronic diseases such as type 2 diabetes, cardiovascular disease, and cancer in the general population.
2. Studies show that lifestyle improvements can lead to lower suPAR levels, which in turn are associated with reduced health risks.
3. SuPAR is now recognized not just as a marker but also as a causal factor in the development of age-related diseases, including atherosclerosis and chronic kidney disease, highlighting the importance of maintaining low suPAR levels as part of a long-term health strategy.

suPAR is the central biomarker used in all of SuPAR Health’s services. The test is performed using suPARnostic^®, a patented and CE-IVD approved technology that is validated for use in clinical decision-making.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

AUTHORS: Rasmussen, L. J. H., Petersen, J. E. V., Eugen-Olsen, J.

PUBLISHED: 02 December 2021

AI GENERATED SUMMARY

Discusses the role of suPAR as a biomarker for chronic systemic inflammation, highlighting its potential in diagnosing and predicting inflammation-related diseases.

Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population

AUTHORS: Eugen-Olsen, J., Andersen, O., Linneberg, A.

PUBLISHED: 03 August 2010

AI GENERATED SUMMARY

Demonstrates how circulating suPAR levels can predict the risk of developing cancer, cardiovascular disease, and diabetes, as well as overall mortality in the general population.

Healthy lifestyles reduce suPAR and mortality in a Danish general population study

AUTHORS: Haupt, T. H., Rasmussen, L. J. H., Kallemose, T.

PUBLISHED: 22 January 2019

AI GENERATED SUMMARY

Finds that adopting healthy lifestyle habits significantly reduces suPAR levels and associated mortality rates in the general population.

Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease

AUTHORS: Fagerberg, B., Borné, Y., Barregard, L.

PUBLISHED: 26 October 2016

AI GENERATED SUMMARY

Explores the association between cadmium exposure and elevated suPAR levels, linking this to an increased risk of inflammation and cardiovascular disease.

Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

AUTHORS: Rasmussen, L. J. H., Caspi, A., Ambler, A.

PUBLISHED: 16 July 2020

AI GENERATED SUMMARY

Investigates the relationship between elevated suPAR levels and accelerated aging, suggesting that suPAR can be a marker of biological age and age-related diseases.

Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality

AUTHORS: Törnkvist, P. B. S., Haupt, T. H., Rasmussen, L. J. H.

PUBLISHED: 07 February 2019

AI GENERATED SUMMARY

Finds a linear association between dietary quality and suPAR levels, with poor diet linked to higher suPAR levels and increased mortality risk.

Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals

AUTHORS: Langkilde, A., Hansen, T. W., Ladelund, S.

PUBLISHED: 01 April 2011

AI GENERATED SUMMARY

Demonstrates that elevated plasma suPAR levels serve as a risk marker for developing respiratory cancer in individuals without prior cancer diagnoses.

Plasma suPAR is lowered by smoking cessation: a randomized controlled study

AUTHORS: Eugen-Olsen, J., Ladelund, S., Sørensen, L. T.

PUBLISHED: 01 January 2016

AI GENERATED SUMMARY

This study shows that smoking cessation significantly reduces plasma suPAR levels, suggesting its utility as a marker of inflammation and smoking-related health risks.

Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis, and alcohol use

AUTHORS: Tuomi, H., Kultti, J., Danielsson, J.

PUBLISHED: 01 January 2014

AI GENERATED SUMMARY

Investigates the relationship between suPAR levels and liver disease severity in alcoholics, with higher levels correlating with more severe liver fibrosis and alcohol use.

Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants

AUTHORS: Haastrup, E., Grau, K., Eugen-Olsen, J.

PUBLISHED: 01 January 2014

AI GENERATED SUMMARY

Examines the potential of suPAR as a biomarker for antidepressant use, suggesting that it could reflect underlying inflammation associated with depression and treatment response.

Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen activator receptor)

AUTHORS: Bourassa, K. J., Rasmussen, L. J. H., Danese, A.

PUBLISHED: 01 June 2021

AI GENERATED SUMMARY

This study explores the link between stressful life events and chronic inflammation, demonstrating that elevated suPAR levels are associated with higher levels of stress and long-term inflammation.

suPAR in cardiovascular disease

AUTHORS: Montecillo, J., Pirker, T., Pemberton, C.

PUBLISHED: 29 June 2024

AI GENERATED SUMMARY

Reviews the role of suPAR in cardiovascular disease, emphasizing its potential as a prognostic biomarker for cardiovascular risk and disease progression.

qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: A randomized controlled trial

AUTHORS: Adami, M. E., Kotsaki, A., Antonakos, N.

PUBLISHED: 06 February 2024

AI GENERATED SUMMARY

Investigates the combined use of the qSOFA score and suPAR levels in the emergency department for early detection of sepsis and guidance on antibiotic treatment, demonstrating improved patient outcomes.

Role of soluble urokinase type plasminogen activator receptor (suPAR) in predicting mortality, readmission, length of stay and discharge in emergency patients: A systematic review and meta-analysis

AUTHORS: Rehan, S. T., Hussain, H. U., Ali, E.

PUBLISHED: 29 September 2023

AI GENERATED SUMMARY

A systematic review and meta-analysis exploring the role of suPAR in predicting various clinical outcomes in emergency patients, such as mortality, readmission rates, length of hospital stay, and discharge.

Role of soluble urokinase-type plasminogen activator receptor in cardiovascular disease

AUTHORS: Ismail, A., & Hayek, S. S.

PUBLISHED: 01 December 2023

AI GENERATED SUMMARY

Examines the role of suPAR in cardiovascular disease, highlighting its involvement in inflammation and its potential as a biomarker for cardiovascular risk and disease progression.

Soluble urokinase plasminogen activator receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease

AUTHORS: Füller, D., Liu, C., Ko, Y. A.

PUBLISHED: 01 October 2023

AI GENERATED SUMMARY

Investigates how lower education levels mediate the effect of suPAR on adverse cardiovascular outcomes in patients with coronary artery disease, suggesting suPAR as a mediator of social determinants of health.

The association of suPAR with cardiovascular risk factors in young and healthy adults

AUTHORS: Wohlwend, N. F., Grossmann, K., Aeschbacher, S.

PUBLISHED: 13 September 2023

AI GENERATED SUMMARY

Examines the relationship between suPAR levels and cardiovascular risk factors in young and healthy adults, suggesting suPAR as an early marker for future cardiovascular risks.

SuPAR in Major Depression: Association with 26 Weeks Antidepressant Response and 10-Year Depression Outcomes

AUTHORS: Haupt, T. H., Elfving, B., Eugen-Olsen, J.

PUBLISHED: 07 September 2023

AI GENERATED SUMMARY

Investigates the association between suPAR levels and the response to antidepressants in major depression, exploring its impact on 26-week treatment response and long-term outcomes.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non-Rheumatic Diseases

AUTHORS: Manfredi, M., Van Hoovels, L., Benucci, M.

PUBLISHED: 19 April 2023

AI GENERATED SUMMARY

Examines the role of suPAR in both autoimmune rheumatic diseases and non-rheumatic conditions, focusing on its potential as a biomarker.

suPAR Links a Dysregulated Immune Response to Tissue Inflammation and Sepsis-induced Acute Kidney Injury

AUTHORS: Nusshag, C., Wei, C., Hahm, E., Hayek, S. S., Li, J., Samelko, B., ... & Reiser, J.

PUBLISHED: 10 April 2023

AI GENERATED SUMMARY

Investigates how suPAR contributes to sepsis-induced acute kidney injury by linking immune dysregulation and tissue inflammation.

Soluble Urokinase Plasminogen Activator Receptor: From Biomarker to Active Participant in Atherosclerosis and Cardiovascular Disease

AUTHORS: Goodchild, T. T., Li, Z., & Lefer, D. J.

PUBLISHED: 01 December 2022

AI GENERATED SUMMARY

Discusses suPAR's evolution from being a biomarker for cardiovascular diseases to actively participating in the development of atherosclerosis and related conditions.

Predictive Value of suPAR in AKI: A Systematic Review and Meta-analysis

AUTHORS: Huang, Y., Huang, S., Zhuo, X., & Lin, M.

PUBLISHED: 01 December 2022

AI GENERATED SUMMARY

A systematic review and meta-analysis assessing the predictive value of suPAR in acute kidney injury (AKI).

Self-Rated Health and Chronic Inflammation are Related and Independently Associated with Hospitalization and Long-Term Mortality in the General Population

AUTHORS: Tavenier, J., Rasmussen, L. J. H., Tolstrup, J.

PUBLISHED: 01 December 2022

AI GENERATED SUMMARY

Explores the relationship between self-rated health, chronic inflammation, and its independent association with hospitalization and long-term mortality in the general population.

Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure

AUTHORS: Hayek, S. S., Tahhan, A. S., Ko, Y. A.

PUBLISHED: 01 October 2022

AI GENERATED SUMMARY

Investigates how suPAR levels influence outcomes in patients with heart failure, contributing to understanding its role in cardiovascular disease prognosis.

suPAR: An Inflammatory Mediator for Kidneys

AUTHORS: Sudhini, Y. R., Wei, C., & Reiser, J.

PUBLISHED: 08 June 2022

AI GENERATED SUMMARY

Reviews the role of suPAR as a mediator of inflammation in kidney diseases, highlighting its potential as a biomarker for kidney injury and disease progression.

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) is Elevated in Caregivers of Patients with Parkinsonism

AUTHORS: Joyce, J., Cabanas, N., Pisharody, R.

PUBLISHED: 01 September 2022

AI GENERATED SUMMARY

Investigates elevated levels of suPAR in caregivers of patients with Parkinsonism, potentially indicating an inflammatory response related to caregiving stress.

Soluble Urokinase-Type Plasminogen Activator Receptor as a Prognostic Marker of Ugandan Children at Risk of Severe and Fatal Malaria

AUTHORS: Stefanova, V., Ngai, M., Weckman, A. M.

PUBLISHED: 15 July 2023

AI GENERATED SUMMARY

Examines suPAR as a prognostic biomarker for identifying Ugandan children at risk of severe and fatal malaria, focusing on its role in predicting outcomes.

Circulating suPAR Associates with Severity and In-Hospital Progression of COVID-19

AUTHORS: Chalkias, A., Skoulakis, A., Papagiannakis, N.

PUBLISHED: 01 December 2022

AI GENERATED SUMMARY

Investigates how circulating suPAR levels correlate with the severity and in-hospital progression of COVID-19, highlighting its potential as a prognostic marker in COVID-19 management.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalization in Patients with COVID-19

AUTHORS: Enocsson, H., Idoff, C., Gustafsson, A.

PUBLISHED: 01 December 2021

AI GENERATED SUMMARY

Explores the predictive ability of suPAR for the severity of COVID-19 and the length of hospital stays, highlighting its potential as a biomarker for disease progression.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

AUTHORS: Rasmussen, L. J. H., Petersen, J. E. V., & Eugen-Olsen, J.

PUBLISHED: 02 December 2021

AI GENERATED SUMMARY

Investigates suPAR as a biomarker of chronic systemic inflammation, its role in disease progression, and its potential applications in personalized medicine.

suPAR Cut-Offs for Stratification of Low, Medium, and High-Risk Acute Medical Patients in the Emergency Department

AUTHORS: Santeri, S., Peter, A. A., Kristiina, N.

PUBLISHED: 03 November 2021

AI GENERATED SUMMARY

Discusses how different levels of suPAR can be used to stratify the risk of acute medical patients in the emergency department, aiding in decision-making and patient management.

suPAR, a Circulating Kidney Disease Factor

AUTHORS: Wei, C., Spear, R., Hahm, E.

PUBLISHED: 06 October 2021

AI GENERATED SUMMARY

Explores suPAR as a key factor in kidney disease, examining its role as a circulating marker for kidney injury and potential therapeutic target.

Pre-Hospital suPAR, Lactate, and CRP Measurements for Decision-Making: A Prospective, Observational Study of Patients Presenting Non-Specific Complaints

AUTHORS: Jousi, M., Mäkinen, M., Kaartinen, J.

PUBLISHED: 03 November 2021

AI GENERATED SUMMARY

Examines the use of pre-hospital suPAR, lactate, and CRP levels in decision-making for patients with non-specific complaints, highlighting suPAR's potential in triage.

Serum Levels of the Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage Over Time

AUTHORS: Enocsson, H., Lukic, T., Ziegelasch, M.

PUBLISHED: 01 November 2021

AI GENERATED SUMMARY

Investigates the correlation between suPAR levels and disease activity in early rheumatoid arthritis, demonstrating that suPAR reflects joint damage progression over time.

Soluble Urokinase-Type Plasminogen Activator Receptor Predicts Peripheral Artery Disease Severity and Outcomes

AUTHORS: Höbaus, C., Ursli, M., Yussef, S. M.

PUBLISHED: 01 February 2021

AI GENERATED SUMMARY

Examines the role of suPAR in predicting the severity of peripheral artery disease (PAD) and its potential in forecasting clinical outcomes in PAD patients.

Soluble Urokinase Receptor (suPAR) in COVID-19-Related AKI

AUTHORS: Azam, T. U., Shadid, H. R., Blakely, P.

PUBLISHED: 01 December 2020

AI GENERATED SUMMARY

Investigates the relationship between suPAR levels and acute kidney injury (AKI) in COVID-19 patients, showing its potential as a biomarker for early detection of kidney complications.

Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

AUTHORS: Rasmussen, L. J. H., Caspi, A., Ambler, A.

PUBLISHED: 01 January 2021

AI GENERATED SUMMARY

Explores the association between elevated suPAR levels and accelerated aging, demonstrating its potential role as a marker for age-related diseases and inflammatory processes.

suPAR is Associated with Death and Adverse Cardiovascular Outcomes in Patients with Suspected Coronary Artery Disease

AUTHORS: Hodges, G., Lyngbæk, S., Selmer, C.

PUBLISHED: 01 July 2020

AI GENERATED SUMMARY

Investigates the association between suPAR levels and mortality in patients with suspected coronary artery disease, linking it to worse cardiovascular outcomes and higher mortality.

Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children

AUTHORS: Weidemann, D. K., Abraham, A. G., Roem, J. L.

PUBLISHED: 01 May 2020

AI GENERATED SUMMARY

Investigates the role of suPAR in the progression of chronic kidney disease (CKD) in children, highlighting its potential as a predictive biomarker for CKD progression.

Analytical, Biochemical and Clearance Considerations of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Healthy Individuals

AUTHORS: Chew-Harris, J., Appleby, S., Richards, A. M.

PUBLISHED: 01 August 2019

AI GENERATED SUMMARY

Reviews the analytical and biochemical properties of suPAR in healthy individuals, with a focus on its clearance mechanisms and implications for its use as a biomarker.

Healthy Lifestyles Reduce suPAR and Mortality in a Danish General Population Study

AUTHORS: Haupt, T. H., Rasmussen, L. J. H., Kallemose, T.

PUBLISHED: 07 February 2019

AI GENERATED SUMMARY

Demonstrates that healthy lifestyles, such as physical activity and proper nutrition, significantly reduce suPAR levels and associated mortality in the general population.

Soluble Urokinase Plasminogen Activator Receptor is Linearly Associated with Dietary Quality and Predicts Mortality

AUTHORS: Törnkvist, P. B. S., Haupt, T. H., Rasmussen, L. J. H.

PUBLISHED: 01 January 2019

AI GENERATED SUMMARY

Investigates the association between dietary quality and suPAR levels, showing that poor dietary quality is linked to higher suPAR levels and an increased risk of mortality.

Cumulative Childhood Risk is Associated with a New Measure of Chronic Inflammation in Adulthood

AUTHORS: Rasmussen, L. J. H., Moffitt, T. E., Eugen-Olsen, J.

PUBLISHED: 09 May 2018

AI GENERATED SUMMARY

Explores how cumulative childhood risk factors are linked to elevated suPAR levels in adulthood, which serve as a marker of chronic inflammation.

suPAR is Associated with Risk of Future Acute Surgery and Post-Operative Mortality in Acutely Admitted Medical Patients

AUTHORS: Meyer, J., Alstrup, M., Rasmussen, L. J. H.

PUBLISHED: 18 January 2018

AI GENERATED SUMMARY

Examines the association between elevated suPAR levels and the risk of requiring acute surgery or experiencing post-operative mortality in acutely admitted medical patients.

suPAR Predicts Postoperative Complications and Mortality in Patients with Asymptomatic Aortic Stenosis

AUTHORS: Hodges, G. W., Bang, C. N., Eugen-Olsen, J.

PUBLISHED: 31 January 2018

AI GENERATED SUMMARY

Investigates how elevated suPAR levels predict postoperative complications and mortality in patients with asymptomatic aortic stenosis, underlining its potential role in risk assessment for cardiovascular surgery.

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-Based Malmö Diet and Cancer Study

AUTHORS: Schulz, C. A., Persson, M., Christensson, A.

PUBLISHED: 01 January 2017

AI GENERATED SUMMARY

Explores the association between suPAR levels and impaired kidney function in a population-based cohort, suggesting that suPAR may serve as a marker for early kidney disease.

Soluble Urokinase Receptor (suPAR) Predicts Microalbuminuria in Patients at Risk for Type 2 Diabetes Mellitus

AUTHORS: Guthoff, M., Wagner, R., Randrianarisoa, E.

PUBLISHED: 16 January 2017

AI GENERATED SUMMARY

Investigates the predictive role of suPAR in identifying microalbuminuria in patients at risk for type 2 diabetes, suggesting its potential as a biomarker for early diabetic kidney disease.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Acute Care: A Strong Marker of Disease Presence and Severity, Readmission and Mortality

AUTHORS: Rasmussen, L. J., Ladelund, S., Haupt, T. H.

PUBLISHED: 02 September 2016

AI GENERATED SUMMARY

Highlights the role of suPAR as a strong marker for disease presence, severity, readmission, and mortality in acute care settings, emphasizing its utility in emergency medicine.

suPAR: The Unspecific Marker for Disease Presence, Severity, and Prognosis

AUTHORS: Eugen-Olsen, J., & Giamarellos-Bourboulis, E. J.

PUBLISHED: 01 January 2016

AI GENERATED SUMMARY

Discusses the role of suPAR as a nonspecific biomarker for disease presence, severity, and prognosis, and its potential applications in clinical practice.

Soluble Urokinase Plasminogen Activator Receptor and Incidence of Venous Thromboembolism

AUTHORS: Engström, G., Zöller, B., Svensson, P. J.

PUBLISHED: 01 January 2016

AI GENERATED SUMMARY

Investigates the association between suPAR levels and the incidence of venous thromboembolism, suggesting its potential as a marker for thrombotic events.

The Role of the Soluble Urokinase Plasminogen Activator (suPAR) in Children with Pneumonia

AUTHORS: Wrotek, A., & Jackowska, T.

PUBLISHED: 01 January 2015

AI GENERATED SUMMARY

Examines suPAR's role as a biomarker in children with pneumonia, assessing its potential to predict disease severity and complications.

Associations of suPAR with Lifestyle and Cardiometabolic Risk Factors

AUTHORS: Botha, S., Fourie, C. M., Schutte, R.

PUBLISHED: 01 January 2014

AI GENERATED SUMMARY

Investigates the relationship between suPAR levels and various lifestyle factors and cardiometabolic risk factors, including diet and physical activity.

Cardiovascular Risk Prediction in the General Population with Use of suPAR, CRP, and Framingham Risk Score

AUTHORS: Lyngbæk, S., Marott, J. L., Sehestedt, T.

PUBLISHED: 01 January 2013

AI GENERATED SUMMARY

Explores the combined use of suPAR, CRP, and the Framingham Risk Score for better cardiovascular risk prediction in the general population.

Plasma suPAR Levels Are Associated with Mortality, Admission Time, and Charlson Comorbidity Index in the Acutely Admitted Medical Patient

AUTHORS: Haupt, T. H., Petersen, J., Ellekilde, G.

PUBLISHED: 01 January 2012

AI GENERATED SUMMARY

Investigates how elevated suPAR levels in acutely admitted medical patients correlate with mortality, length of hospital stay, and comorbidity severity as assessed by the Charlson Comorbidity Index.

suPAR as a Prognostic Biomarker in Sepsis

AUTHORS: Donadello, K., Scolletta, S., Covajes, C.

PUBLISHED: 01 January 2012

AI GENERATED SUMMARY

Discusses the potential of suPAR as a prognostic biomarker for sepsis, particularly its ability to predict patient outcomes and guide therapeutic interventions.

Why High suPAR Is Not Super—Diagnostic, Prognostic and Potential Pathogenic Properties of a Novel Biomarker in the ICU

AUTHORS: Koch, A., & Tacke, F.

PUBLISHED: 01 January 2011

AI GENERATED SUMMARY

Examines the limitations and challenges of using high suPAR levels as a diagnostic and prognostic marker in intensive care units (ICU), highlighting potential pathogenic roles.

Exploring Soluble Urokinase Plasminogen Activator Receptor and Its Relationship with Arterial Stiffness in a Bi-Ethnic Population: The SAfrEIC-Study

AUTHORS: Schutte, A. E., Myburgh, A., Olsen, M. H.

PUBLISHED: 01 January 2012

AI GENERATED SUMMARY

Explores the relationship between suPAR levels and arterial stiffness in a bi-ethnic population, offering insights into the role of suPAR in cardiovascular health.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Healthy Pregnancy and Preeclampsia

AUTHORS: Toldi, G., Bíró, E., Szalay, B., Stenczer, B.

PUBLISHED: 01 January 2011

AI GENERATED SUMMARY

Investigates the levels of suPAR in healthy pregnancies and in cases of preeclampsia, suggesting its potential role as a marker for pregnancy-related complications.

suPAR: The Molecular Crystal Ball

AUTHORS: Thunø, M., Macho, B., & Eugen-Olsen, J.

PUBLISHED: 01 January 2009

AI GENERATED SUMMARY

This paper discusses suPAR as a potential "molecular crystal ball," suggesting that suPAR can be used to predict disease presence, severity, and progression. It emphasizes its role in inflammatory processes and its potential as a diagnostic and prognostic biomarker in various diseases.

Plasma suPAR is Lowered by Smoking Cessation: A Randomized Controlled Study

AUTHORS: Eugen-Olsen, J., Ladelund, S., & Sørensen, L. T.

PUBLISHED: 01 April 2016

AI GENERATED SUMMARY

This randomized controlled study examines the effect of smoking cessation on plasma suPAR levels. The results indicate that smoking cessation leads to a significant reduction in suPAR levels, highlighting the potential of suPAR as a marker for inflammation and its responsiveness to lifestyle changes such as quitting smoking.

Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease

AUTHORS: Mehta, A., Desai, S. R., Ko, Y. A.

PUBLISHED: 22 February 2020

AI GENERATED SUMMARY

This study explores the sex differences in suPAR levels in patients with coronary artery disease (CAD). It finds that suPAR levels differ between men and women and that these differences are associated with adverse outcomes in CAD, including mortality and major cardiovascular events. The findings highlight suPAR's potential as a gender-specific biomarker for assessing CAD risk.

The science behind suPAR